share_log

Innate Pharma's TELLOMAK Phase 2 Trial: Lacutamab Demonstrates Significant Symptom Relief and Quality-of-Life Improvements In Advanced CTCL, Presented At ASH 2024

Benzinga ·  Dec 9, 2024 02:07
  • Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment